Serina Historical Income Statement

SER Stock

4.79 0.64 15.42%

Historical analysis of Serina Therapeutics income statement accounts such as Cost Of Revenue of 162.4 K, Total Operating Expenses of 6.4 M, Interest Expense of 5.1 M or Interest Income of 1.5 K can show how well Serina Therapeutics performed in making a profits. Evaluating Serina Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Serina Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Serina Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Serina Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Serina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.

About Serina Income Statement Analysis

Serina Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Serina Therapeutics shareholders. The income statement also shows Serina investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Serina Therapeutics Income Statement Chart

As of 12/18/2024, Interest Expense is likely to grow to about 5.1 M, while Depreciation And Amortization is likely to drop slightly above 124.5 K.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Serina Therapeutics. It is also known as Serina Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Serina Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Serina Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Serina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.As of 12/18/2024, Interest Expense is likely to grow to about 5.1 M, while Depreciation And Amortization is likely to drop slightly above 124.5 K.

	2021	2022	2024 (projected)
Total Revenue	3.0M	500K	134.9K
Depreciation And Amortization	131K	132K	124.5K

Total Revenue Depreciation And Amortization

Serina Therapeutics income statement Correlations

	Depreciation And Amortization	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Expense	Net Interest Income	Interest Income	Selling General Administrative	Net Income From Continuing Ops	Reconciled Depreciation
Depreciation And Amortization		0.24	-0.25	0.83	-0.74	-0.73	0.83	-0.67	1.0	0.8	-0.37	0.67	-0.38	0.84	-0.58	0.81	0.81	0.62	0.81	-0.78
Total Revenue	0.24		0.88	0.32	-0.01	-0.02	0.73	0.01	0.24	0.34	0.31	0.69	0.33	0.05	-0.63	0.72	0.72	0.6	0.71	-0.69
Gross Profit	-0.25	0.88		-0.09	0.36	0.34	0.32	0.34	-0.25	-0.06	0.5	0.36	0.53	-0.35	-0.35	0.32	0.32	0.3	0.31	-0.31
Other Operating Expenses	0.83	0.32	-0.09		-0.92	-0.93	0.78	-0.9	0.85	1.0	-0.67	0.41	-0.66	0.63	-0.28	0.7	0.68	0.4	0.71	-0.61
Operating Income	-0.74	-0.01	0.36	-0.92		1.0	-0.54	0.99	-0.75	-0.92	0.88	-0.12	0.88	-0.62	-0.03	-0.46	-0.43	-0.06	-0.48	0.43
Ebit	-0.73	-0.02	0.34	-0.93	1.0		-0.55	1.0	-0.75	-0.92	0.88	-0.13	0.87	-0.59	-0.02	-0.45	-0.43	-0.07	-0.47	0.42
Research Development	0.83	0.73	0.32	0.78	-0.54	-0.55		-0.5	0.83	0.77	-0.1	0.87	-0.09	0.54	-0.77	0.94	0.94	0.79	0.93	-0.9
Ebitda	-0.67	0.01	0.34	-0.9	0.99	1.0	-0.5		-0.69	-0.9	0.91	-0.06	0.9	-0.54	-0.09	-0.4	-0.37	0.0	-0.41	0.37
Cost Of Revenue	1.0	0.24	-0.25	0.85	-0.75	-0.75	0.83	-0.69		0.82	-0.39	0.67	-0.4	0.83	-0.57	0.81	0.81	0.61	0.81	-0.78
Total Operating Expenses	0.8	0.34	-0.06	1.0	-0.92	-0.92	0.77	-0.9	0.82		-0.67	0.39	-0.66	0.6	-0.25	0.68	0.66	0.39	0.7	-0.59
Income Before Tax	-0.37	0.31	0.5	-0.67	0.88	0.88	-0.1	0.91	-0.39	-0.67		0.36	1.0	-0.4	-0.49	-0.05	-0.01	0.39	-0.07	0.03
Total Other Income Expense Net	0.67	0.69	0.36	0.41	-0.12	-0.13	0.87	-0.06	0.67	0.39	0.36		0.37	0.37	-0.98	0.82	0.85	0.94	0.79	-0.81
Net Income	-0.38	0.33	0.53	-0.66	0.88	0.87	-0.09	0.9	-0.4	-0.66	1.0	0.37		-0.42	-0.5	-0.05	-0.01	0.4	-0.07	0.02
Income Tax Expense	0.84	0.05	-0.35	0.63	-0.62	-0.59	0.54	-0.54	0.83	0.6	-0.4	0.37	-0.42		-0.27	0.71	0.69	0.33	0.73	-0.67
Interest Expense	-0.58	-0.63	-0.35	-0.28	-0.03	-0.02	-0.77	-0.09	-0.57	-0.25	-0.49	-0.98	-0.5	-0.27		-0.72	-0.76	-0.95	-0.69	0.71
Net Interest Income	0.81	0.72	0.32	0.7	-0.46	-0.45	0.94	-0.4	0.81	0.68	-0.05	0.82	-0.05	0.71	-0.72		1.0	0.73	1.0	-0.96
Interest Income	0.81	0.72	0.32	0.68	-0.43	-0.43	0.94	-0.37	0.81	0.66	-0.01	0.85	-0.01	0.69	-0.76	1.0		0.77	0.99	-0.96
Selling General Administrative	0.62	0.6	0.3	0.4	-0.06	-0.07	0.79	0.0	0.61	0.39	0.39	0.94	0.4	0.33	-0.95	0.73	0.77		0.72	-0.64
Net Income From Continuing Ops	0.81	0.71	0.31	0.71	-0.48	-0.47	0.93	-0.41	0.81	0.7	-0.07	0.79	-0.07	0.73	-0.69	1.0	0.99	0.72		-0.94
Reconciled Depreciation	-0.78	-0.69	-0.31	-0.61	0.43	0.42	-0.9	0.37	-0.78	-0.59	0.03	-0.81	0.02	-0.67	0.71	-0.96	-0.96	-0.64	-0.94

Click cells to compare fundamentals

Serina Therapeutics Account Relationship Matchups

Pair Trading with Serina Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Serina Stock

0.79	VALN	Valneva SE ADR	Pair Corr
0.62	ERNA	Eterna Therapeutics	Pair Corr

Moving against Serina Stock

0.73	GILD	Gilead Sciences	Pair Corr
0.71	BMY	Bristol Myers Squibb	Pair Corr
0.62	DYAI	Dyadic International	Pair Corr
0.53	ESPR	Esperion Therapeutics Buyout Trend	Pair Corr

The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.

The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Serina Stock Analysis

When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Serina Historical Income Statement

About Serina Income Statement Analysis

Serina Therapeutics Income Statement Chart

Other Operating Expenses

Serina Therapeutics income statement Correlations

Serina Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Serina Therapeutics

Moving together with Serina Stock

Moving against Serina Stock

Additional Tools for Serina Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Depreciation And Amortization
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax
Interest Income	+ 1.0	Net Interest Income

Interest Expense	- 0.98	Total Other Income Expense Net
Reconciled Depreciation	- 0.96	Interest Income
Reconciled Depreciation	- 0.96	Net Interest Income
Selling General Administrative	- 0.95	Interest Expense
Reconciled Depreciation	- 0.94	Net Income From Continuing Ops
Ebit	- 0.93	Other Operating Expenses